These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18094111)

  • 21. Mucosal and systemic adjuvant effects of cholera toxin and Cry1Ac protoxin on the specific antibody response to HIV-1 C4/V3 peptides are different and depend on the antigen co-administered.
    Esquivel-Pérez R; Moreno-Fierros L
    Viral Immunol; 2005; 18(4):695-708. PubMed ID: 16359236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal immunization of cocktail/fusion protein containing Tir along with ΔG active fragment of Zot as mucosal adjuvant confers enhanced immunogenicity and reduces E. coli O157:H7 shedding in mice.
    Shekar A; Ramlal S; Jeyabalaji JK; Sripathy MH
    Int Immunopharmacol; 2018 Oct; 63():211-219. PubMed ID: 30103196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The immunological consequences of feeding cholera toxin. I. Feeding cholera toxin suppresses the induction of systemic delayed-type hypersensitivity but not humoral immunity.
    Kay RA; Ferguson A
    Immunology; 1989 Mar; 66(3):410-5. PubMed ID: 2703255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral immunization with F4 fimbriae and CpG formulated with carboxymethyl starch enhances F4-specific mucosal immune response and modulates Th1 and Th2 cytokines in weaned pigs.
    Delisle B; Calinescu C; Mateescu MA; Fairbrother JM; Nadeau É
    J Pharm Pharm Sci; 2012; 15(5):642-56. PubMed ID: 23331903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice.
    Brennan FR; Bellaby T; Helliwell SM; Jones TD; Kamstrup S; Dalsgaard K; Flock JI; Hamilton WD
    J Virol; 1999 Feb; 73(2):930-8. PubMed ID: 9882293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin.
    Tochikubo K; Isaka M; Yasuda Y; Kozuka S; Matano K; Miura Y; Taniguchi T
    Vaccine; 1998; 16(2-3):150-5. PubMed ID: 9607023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
    Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
    J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant synergy: the effects of nasal coadministration of adjuvants.
    Moschos SA; Bramwell VW; Somavarapu S; Alpar HO
    Immunol Cell Biol; 2004 Dec; 82(6):628-37. PubMed ID: 15550121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice.
    Strindelius L; Filler M; Sjöholm I
    Vaccine; 2004 Sep; 22(27-28):3797-808. PubMed ID: 15315861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Mizokami M; Kozuka S; Taniguchi T; Matano K; Maeyama J; Mizuno K; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2001 Jan; 19(11-12):1460-6. PubMed ID: 11163669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1-type helper T cells with a single nasal coadministration in mice.
    Sasaki K; Kato M; Takahashi T; Ochi S; Ichinose Y; Shiraki K; Asano Y; Iwanaga M; Tsuji T
    J Med Virol; 2003 Jun; 70(2):329-35. PubMed ID: 12696126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin/chitosan (JY) adjuvant enhances the mucosal immunity of human papillomavirus 16 L1 virus-like particles in mice.
    Ma F; Zhang Q; Zheng L
    Biotechnol Lett; 2015 Apr; 37(4):773-7. PubMed ID: 25472872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
    McCluskie MJ; Davis HL
    J Immunol; 1998 Nov; 161(9):4463-6. PubMed ID: 9794366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
    Porgador A; Staats HF; Faiola B; Gilboa E; Palker TJ
    J Immunol; 1997 Jan; 158(2):834-41. PubMed ID: 8993001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of natural and recombinant cholera toxin B subunit as stimulatory factors in intranasal immunization.
    de Geus B; Dol-Bosman M; Scholten JW; Stok W; Bianchi A
    Vaccine; 1997 Jul; 15(10):1110-3. PubMed ID: 9269054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nasally administered cholera toxin A-subunit acts as a mucosal adjuvant.
    Campos EA; Namikoshi J; Maeba S; Yamamoto M; Fukumoto M; Yamamoto H
    J Oral Sci; 2003 Mar; 45(1):25-31. PubMed ID: 12816361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit.
    Wu HY; Russell MW
    Infect Immun; 1993 Jan; 61(1):314-22. PubMed ID: 8418053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral administration of a dominant T-cell determinant peptide inhibits allergen-specific TH1 and TH2 cell responses in Cry j 2-primed mice.
    Hirahara K; Saito S; Serizawa N; Sasaki R; Sakaguchi M; Inouye S; Taniguchi Y; Kaminogawa S; Shiraishi A
    J Allergy Clin Immunol; 1998 Dec; 102(6 Pt 1):961-7. PubMed ID: 9847437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.